Bruteridine

Bruteridine (Brutieridin): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Nomenclature

Bruteridine — also rendered in the scientific literature as brutieridin — is the name used in dietary supplement and nutraceutical contexts for a compound whose systematic chemical designation is the 3-hydroxy-3-methylglutaryl (HMG) neohesperidoside of hesperetin. The 3-hydroxy-3-methylglutaryl neohesperidoside of hesperetin (brutieridin) was isolated and detected from the fruits of Citrus bergamia. It is registered in the PubChem database as Brutieridin, with molecular formula C₃₄H₄₂O₁₉ and CID 45279710.

Brutieridin is a flavanone glycoside. More specifically, the glutaryl derivatives of hesperidin and naringin — brutieridin and melitidin — contain a 3-hydroxy-3-methylglutaryl moiety with a structural similarity to the natural substrate of HMG-CoA reductase (HMGCR), and are likely to exhibit statin-like activity.

Botanical Source

Bruteridine is found exclusively in Citrus bergamia Risso & Poit. (bergamot orange), a citrus fruit cultivated primarily in a narrow coastal strip of the Calabria region of southern Italy. Brutieridin and melitidin are not found in any other citrus species. Brutieridin and melitidin are newly identified flavonoid glycosides from bergamot fruit, containing HMG moieties. Approximately 300–500 ppm of brutieridin and 150–300 ppm of melitidin are found in bergamot juice.

Within the fruit, bruteridine is present alongside a broader panel of flavanone glycosides. The main flavanones in bergamot juice are brutieridin, naringin, neohesperidin, melitidin, neoeriocitrin, and eriodictyol-7-O-neohesperidoside-6″-O-HMG. The Bergamot Polyphenolic Fraction (BPF) — a purified extract derived from bergamot juice through solvent extraction and chromatographic techniques — contains particularly high concentrations of flavanones such as naringin (up to 400 mg/L), neoeriocitrin (~250 mg/L), and neohesperidin (~150 mg/L), which are rare or absent in other citrus fruits like lemons and oranges. The fruit's juice and the albedo (the white pith between the rind and the pulp) are the primary plant fractions from which bruteridine and the broader polyphenolic complex are extracted.

Discovery and First Isolation

A research group identified, in the whole fruit juice of bergamot, the presence of two new statin-like flavonoids: brutieridin (1) and melitidin (2). The inhibitory effect on HMG-CoA reductase of these new flavonoids, bearing the 3-hydroxy-3-methylglutaric acid (HMG) moiety, was compared in vitro against commercial statin drugs. The structures of both compounds were elucidated using spectroscopic approaches. HPLC and mass spectrometry confirmed the structures of both compounds with high accuracy. The presence of such statin-like compounds was reported for the first time in this fruit in 2009; in particular, the structures of the 6-O-glucosyl HMG derivatives of naringin and neohesperidin were elucidated through NMR and HRMS experiments.

Bergamot juice and albedo have no important industrial applications, in evident disparity with other citrus fruits. The albedo layer, rich in pectin and several flavonoids, had never been investigated in detail for value-added compounds such as nutraceuticals. What remains after the extraction of the volatile fraction is considered industrial waste with its relative economic and environmental disadvantages. The discovery of bruteridine and melitidin in this waste fraction opened avenues for valorization of the bergamot by-product stream.

Physical and Chemical Properties

Brutieridin is a flavanone glycoside naturally present in the fruit of the bergamot plant (Citrus bergamia), which is cultivated in Southern Italy. Melitidin and brutieridin are flavanone diglycosides of naringenin and hesperetin, respectively, carrying the 3-hydroxy-3-methylglutaric acid (HMG) moiety. The presence of the 3-hydroxy-3-methylglutaryl ester moiety was confirmed by basic hydrolysis experiments carried out using NaOH 0.1 M; the experiments showed the formation, after only 30 minutes, of neoeriocitrin. This hydrolysis behavior distinguishes the HMG ester bond from the glycosidic linkages and is relevant to understanding the compound's metabolic fate.

Common Forms and Preparations in Commerce

Bruteridine is not typically marketed as an isolated single compound in dietary supplement products. It is commercially encountered as a component of standardized bergamot fruit extracts, most prominently the proprietary Bergamot Polyphenolic Fraction (BPF). The flavones in commercial standardized bergamot products are composed of neoeriocitrin, naringin, and neohesperidin, as well as melitidin and bruteridine. The BPF is typically standardized by total polyphenol content, with products commonly labeled at 38% polyphenols. Supplement forms include oral capsules and tablets containing measured doses of the BPF extract. Capsules containing 500 mg of bergamot polyphenolic fraction with 50 mg of ascorbic acid have been employed in clinical research.

2. Traditional and Historical Use

Bruteridine and melitidin present significant potential for anticholesterolemic activity, adding to the known nutraceutical benefits of bergamot and underscoring its agricultural importance in the Calabrian region. The broader parent plant, Citrus bergamia, has a well-established ethnobotanical history in Calabria and adjacent areas of southern Italy, where the fruit's juice and rind have been used in local folk medicine traditions.

It must be stated clearly, however, that bruteridine itself was not identified as a discrete phytochemical until 2009. Prior traditional uses of bergamot were empirically directed at the whole fruit, juice, essential oil, or albedo, without any knowledge of bruteridine as a specific active constituent. Any attributions of traditional use thus belong to bergamot as a botanical source rather than to bruteridine as an isolated molecule. No documented traditional preparations have been identified in the peer-reviewed literature that specifically reference or intentionally concentrate bruteridine. The compound should therefore be understood as a relatively recently characterized phytochemical within an established ethnobotanical plant, rather than an ingredient with its own independent traditional history.

3. Key Constituents, Chemistry, and Mechanisms of Action

Chemical Relationship to Statins

The most pharmacologically distinctive feature of bruteridine is its possession of a 3-hydroxy-3-methylglutaric acid (HMG) ester moiety. The peculiarity of bergamot lies in the presence of two new statin-like molecules that are esters of 3-hydroxy-3-methylglutaric (HMG) acid which, when linked to CoA, represents the key intermediate in cholesterol biosynthesis. The flavonoid conjugates brutieridin and melitidin were recently quantified in bergamot fruit extracts and identified to be structural analogues of statins, lipids-concentration-lowering drugs that inhibit HMGR. Density functional theory was applied to study the binding mode of these new flavonoids as possible inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), an enzyme that catalyzes the four-electron reduction of HMG-CoA to mevalonate, the committed step in the biosynthesis of sterols.

HMG-CoA Reductase Inhibition

The rate-limiting step in endogenous cholesterol biosynthesis is controlled by an enzyme called 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This enzyme is responsible for converting HMG-CoA into mevalonic acid, which eventually becomes cholesterol. Because of its critical role, HMG-CoA reductase is the exact biological target of prescription statin medications, which bind to the enzyme and inhibit its activity to lower circulating cholesterol. Because brutieridin and melitidin found in Bergamot BPF contain an HMG moiety, they act as natural, competitive inhibitors of HMG-CoA reductase. They physically bind to the active site of the enzyme, effectively slowing down the liver's production of cholesterol.

However, the strength of this evidence requires careful characterization. More recent studies suggest there is minimal to no significant evidence of statin-like activity. Bergamot extract contains a family of polyphenolic flavonoids — most notably brutieridin and melitidin — that structurally resemble the active moiety of statin drugs. The hypothesis is that these compounds partially inhibit HMG-CoA reductase, activate AMPK to suppress hepatic lipid synthesis, and reduce oxidative modification of LDL particles. The original structural analogy and in vitro evidence for direct HMGR inhibition therefore remain contested, and the bulk of mechanistic evidence is preclinical.

In cell-based studies, bruteridine was shown to modulate expression of LDL receptor (LDLR). Melitidin produced a +3.7-fold increase in LDLR and a +4.32-fold change in PCSK9 expression levels versus control, and brutieridin stimulated the LDLR expression by +3.1-fold compared with control, while no effect was observed on PCSK9 levels. This suggests that bruteridine may lower LDL cholesterol partly through upregulation of LDL receptor expression, rather than solely through direct enzymatic inhibition.

The glutaryl derivatives of hesperidin and naringin (brutieridin and melitidin) contain a 3-hydroxy-3-methylglutaryl moiety with a structural similarity to the natural substrate of HMGCR and are likely to exhibit statin-like activity. Preclinical and clinical studies have provided evidence that different forms of orally administered bergamot can reduce total cholesterol (TC) and LDL-C. Although clear evidence accounts for a beneficial role of supplementation with bergamot fruit extract (BFE) in hyperlipidemic patients, the molecular mechanism contributing to this effect still needs to be clarified.

AMPK Activation

A second mechanism that has been characterized in preclinical research is the activation of AMP-activated protein kinase (AMPK). BPF has been shown to contain large amounts of glycosylated polyphenols — in particular bruteridine and melitidine — which have been shown to possess statin-like activity, thereby inhibiting HMG-CoA reductase. Furthermore, BPF has been demonstrated to modulate AMP (adenosine monophosphate)-activated protein kinase (AMPK), which plays a key role in the regulation of the metabolic pathways involved in ATP production in mammalian cells. AMPK activation suppresses hepatic fatty acid and cholesterol synthesis and is also implicated in improved insulin sensitivity, providing a mechanistic basis for the reported glucose-lowering effects of BPF in metabolic syndrome patients.

Multi-Target Cholesterol Regulation

Recent scientific investigations have elucidated that the cholesterol-lowering effects of brutieridin, a flavanone glycoside found in Citrus bergamia, are not attributable to a single mode of action but rather a coordinated regulation of multiple key targets in cholesterol homeostasis. A comprehensive analysis reveals a multi-pronged mechanism of action against cholesterol synthesis that extends beyond the initial hypothesis of direct HMG-CoA reductase inhibition. Bergamot contains flavanones — including brutieridin, melitidin, and HMG-neoeriocitrin — which have been demonstrated to inhibit HMG-CoA reductase like statins. Flavonoids such as melitidin and brutieridin in combination with other flavonoid glycosides present in bergamot are likely to be responsible for lipid-lowering effects of this fruit.

Investigations of bergamot fruit extract (BFE) and its principal components — neoeriocitrin, naringin, neohesperidin, melitidin, and brutieridin — for their ability to regulate cholesterol levels in HepG2 and Caco-2 cells showed that BFE at increasing concentrations decreased the levels of total and free cholesterol in HepG2 cells. These hepatoma and intestinal cell line studies represent the primary body of in vitro mechanistic evidence.

Vascular and Antioxidant Effects

In animal models, the BPF complex containing bruteridine has been associated with effects on vascular function. Evidence has accumulated demonstrating that bergamot polyphenolic fraction (BPF) is able to produce a hypolipemic effect accompanied by improvement of endothelial function and reduction of cardiometabolic risk. This has been assessed in both animal models of hyperlipemia as well as in patients.

4. Scientific Evidence by Area of Use

4.1 Lipid-Lowering (Hypocholesterolemic) Effects

Preclinical Evidence

Three flavonoids — brutieridin, melitidin, and neoeriocitrin — have been shown to own activities that mimic the effects of a statin, simvastatin. After successful trials in a rat model which showed a significant reduction in serum cholesterol, triglycerides, and LDL levels, coupled with an increase in HDL levels, researchers next investigated the effect of brutieridin and melitidin in human patients with high LDL and high triglyceride levels.

Clinical Evidence

Bruteridine has not been tested as an isolated compound in randomized controlled trials in humans. All clinical evidence pertains to bergamot polyphenolic fractions (BPF) or bergamot juice preparations that contain bruteridine as one of several co-occurring flavanones. Attribution of observed effects specifically to bruteridine, as opposed to the whole BPF complex, cannot be made from current human data.

The results of five different clinical trials using bergamot in various forms suggest the polyphenol fraction can lower LDL-C and total cholesterol. A prospective, open-label, parallel group, placebo-controlled study with 77 human subjects with elevated LDL and triglycerides were administered placebo, rosuvastatin 10 mg, rosuvastatin 20 mg, bergamot polyphenol fraction (BPF), or bergamot polyphenol fraction with rosuvastatin. The total duration of the study was 30 days. Both doses of rosuvastatin and BPF reduced total cholesterol, LDL, and urinary mevalonate.

A 30-day randomized trial demonstrated that 500 mg/day of BPF significantly reduced total cholesterol (−21.8%), LDL-C (−24.1%), and triglycerides (−30.5%) compared to placebo in individuals with hyperlipidemia.

Several studies suggested that bergamot polyphenols can reduce triglycerides and increase HDL-C; however, the results were not consistent across all studies. One possible explanation for this variability is that bergamot preparation, extraction, and standardization varied in several studies. Consistently in all of the clinical trials, bergamot appeared to be well tolerated, with studies ranging from 30 days to 6 months.

A 2024 randomized, double-blind, placebo-controlled trial (registered on PMC) assessed a nutraceutical blend of bergamot and artichoke extracts in 90 individuals with suboptimal cholesterol levels. After 6 weeks, the active-treated group experienced significant improvements in levels of triglycerides, apolipoprotein B-100, and apolipoprotein AI versus baseline. Total cholesterol, LDL-C, non-HDL-C, and hs-CRP also significantly decreased in the active-treated group compared to both baseline and placebo. At the 12-week follow-up, individuals allocated to the combined nutraceutical experienced a significant improvement in TC, LDL-C, non-HDL-C, TG, Apo B-100, Apo AI, glucose, alanine transaminase (ALT), gamma-glutamyl transferase (gGT), hs-CRP, several indexes of non-alcoholic fatty liver disease (NAFLD), and brachial pulse volume in comparison with baseline. Improvements in TC, LDL-C, non-HDL-C, TG, fatty liver index, hs-CRP, and endothelial reactivity were also detected compared to placebo. This was a combination product, so effects cannot be attributed to bergamot or bruteridine alone.

Combination with Statins

Researchers have hypothesized that the use of natural bergamot-derived polyphenols may allow patients undergoing statin treatment to reduce effective doses while achieving target lipid values. One study observed an equivalent reduction in LDL cholesterol when adding bergamot to simvastatin 20 mg with respect to those who received simvastatin 40 mg. A 2013 study reported that the bergamot polyphenol fraction effectively reduced total cholesterol, LDL, and urinary mevalonate and was safe when used alone or in combination with rosuvastatin over a 30-day period.

Strength of Evidence

Preclinical and clinical studies have provided evidence that different forms of orally administered bergamot can reduce total cholesterol and LDL-C. Although clear evidence accounts for a beneficial role of supplementation with bergamot fruit extract in hyperlipidemic patients, the molecular mechanism contributing to this effect still needs to be clarified. Clinical evidence corroborates preclinical findings, demonstrating that bergamot supplement reduces lipid levels when administered at 200 to 1500 mg/day. However, results across trials vary significantly due to differences in participant characteristics, dosage regimens, extraction methods, and the presence of additional bioactive compounds. Evidence for bruteridine as an isolated compound is preclinical only. Human clinical data pertain to whole bergamot extracts. It would be vital to solidly establish which is the most effective way — in terms of lipid-lowering effect — of bergamot supplementation in humans, including either isolation of certain flavonoids, whole polyphenols extraction, or whole bergamot juice extract.

4.2 Glucose Metabolism and Metabolic Syndrome

Several clinical trials with BPF preparations have also measured effects on blood glucose. The nutraceutical approach to the management of metabolic syndrome might be a promising strategy in the prevention of cardio-metabolic risk. Low-dose bergamot-derived polyphenolic fraction (BPF) has been proven effective in patients with metabolic syndrome, as demonstrated by a concomitant improvement in lipemic and glycemic profiles.

BPF administration resulted in a statistically significant reduction of body weight and in a trend for body mass index decrease. No significant differences in other metabolic parameters were observed. These findings suggest that BPF, at the daily dose of 1000 mg for 30 days, could be an effective and safe agent to prevent weight gain associated with atypical antipsychotic use. However, further clinical trials with adequately powered and well-designed methodology are needed to better explore BPF effectiveness.

At the 12-week follow-up in a 2024 trial, individuals allocated to the combined nutraceutical experienced a significant improvement in glucose and several indexes of NAFLD, among other metabolic parameters. Evidence here is preliminary; glucose effects have been observed in some trials involving BPF, but again, isolation of bruteridine's specific contribution is not possible from existing data.

4.3 Vascular/Endothelial Function

At the 12-week follow-up, individuals allocated to the combined nutraceutical also experienced significant improvements in brachial pulse volume and endothelial reactivity compared to placebo. BPF has been studied in vitro for effects on pro-angiogenic (myeloid angiogenic) cells. Myeloid angiogenic cells (MACs) play a key role in endothelial repairing processes and functionality, but their activity may be impaired by the lipotoxic effects of some molecules. Among the dietary components potentially able to modulate endothelial function in vivo, polyphenolic compounds represent serious candidates. A comprehensive multidisciplinary approach was applied to shed light on the prospects of bergamot in the framework of lipotoxicity-induced MAC impairment. A pilot bioavailability study was conducted in healthy volunteers to assess the circulating flavanone metabolites in plasma and urine after consumption of bergamot juice.

4.4 Bioavailability

A key consideration for bruteridine's clinical relevance is its bioavailability. As a flavanone diglycoside bearing an HMG ester linkage, bruteridine must survive gastrointestinal hydrolysis in an appropriate form to exert systemic activity. Up to 12 structurally related flavanone metabolites were identified in plasma and urine samples after bergamot juice consumption. Whether bruteridine itself or its hydrolysis products (which would include neoeriocitrin upon cleavage of the HMG ester) are the active circulating forms remains an open question in the literature.

5. Body Systems and Health Areas

• Cardiovascular system / lipid metabolism: The primary and most studied area. Bruteridine-containing BPF extracts have been investigated for effects on LDL cholesterol, HDL cholesterol, total cholesterol, and triglycerides in human trials.
• Metabolic / hepatic: Significant improvement in alanine transaminase (ALT), gamma-glutamyl transferase (gGT), and several indexes of NAFLD has been reported in the active-treated group at 12 weeks in a clinical trial.
• Glycemic regulation: Some clinical trial results with BPF suggest effects on fasting glucose and, in some analyses, glycated hemoglobin, primarily in the context of metabolic syndrome.
• Endothelial / vascular: Vascular protection through enhancement of nitric oxide-mediated vasodilatation and reduction of oxidative stress has been studied in preclinical models.

6. Dosage Forms and Reported Dosages

Bruteridine, as an isolated compound, has no established human dosage. All clinical dosages pertain to standardized bergamot polyphenolic fraction (BPF) preparations in which bruteridine is one of several co-occurring flavanones.

• Capsules containing 500 mg of bergamot polyphenolic fraction with 50 mg of ascorbic acid were used in at least one clinical trial.
• BPF was administered in capsules at the oral daily dose of 1000 mg/day (500 mg twice daily) in a 30-day open-label pilot study.
• 500 mg/day of BPF administered for 60 days was examined in a separate open-label study in antipsychotic-treated patients.
• Clinical evidence demonstrates that bergamot supplement reduces lipid levels when administered at doses ranging from 200 to 1500 mg/day.
• Each capsule of at least one commercial product contains 500 mg of bergamot, which is less than many studies have used (1000–1500 mg).
• Supplements using BPF standardized to 38% polyphenols at doses of 500 mg to 1000 mg daily have shown the most consistent clinical results across multiple trials.

It would be vital to solidly establish which is the most effective way of bergamot supplementation in humans, including either isolation of certain flavonoids, whole polyphenols extraction, or whole bergamot juice extract. Future studies should also focus on determining the exact dose that would reach the maximum benefit on lipid metabolism with no side effects.

7. Safety Considerations and Interactions

General Tolerability

Consistently in all of the clinical trials, bergamot appeared to be well tolerated, with studies ranging from 30 days to 6 months. BPF adjunctive treatment was well tolerated at 500 mg/day dosage: no adverse effects were recorded in one sample during the 60-day treatment period. Moreover, there was a lack of pharmacokinetic effects on hematic concentrations of antipsychotics, confirming the safety profile reported by previous studies.

In an open-label 30-day study, 13 patients completed the study (86.6% completion rate); there were two premature dropouts, one due to treatment-emergent adverse effects (heartburn) and one due to noncompliance with visits. Gastrointestinal effects such as heartburn thus represent a documented, if uncommon, adverse event.

Drug Interactions

While results suggest that bergamot can be safely combined with statins, it is essential to consider the potential for food-drug interactions between the individual flavonoids and statins. This caution arises because flavanone glycosides can theoretically modulate cytochrome P450 enzymes and drug transporter proteins, though the clinical significance of these interactions specifically for bruteridine has not been quantified in dedicated interaction studies. The results of one study suggest a combination of rosuvastatin and BPF were safe when taken together for 30 days. Further research beyond 30 days would be needed to determine if rosuvastatin and BPF can safely continue to be taken in combination.

Evidence Limitations and Knowledge Gaps

Several significant limitations characterize the current evidence base for bruteridine specifically:

• No human clinical trial has tested bruteridine as an isolated compound. All clinical data are derived from studies on complex bergamot polyphenolic fractions containing bruteridine alongside naringin, neoeriocitrin, neohesperidin, melitidin, and other phytochemicals.
• Mechanistic studies — including the original characterization of HMG-CoA reductase inhibition — are primarily in vitro (cell-free or cell-based) or computational (density functional theory modeling). The molecular mechanism contributing to the observed beneficial effect of BFE supplementation in hyperlipidemic patients still needs to be clarified.
• Bioavailability data on bruteridine specifically are limited. Up to 12 structurally related flavanone metabolites were identified in plasma and urine after bergamot juice consumption, but the extent to which intact bruteridine — rather than its hydrolysis products — reaches systemic circulation remains uncertain.
• Several studies suggested that bergamot polyphenols can reduce triglycerides and increase HDL-C; however, the results were not consistent across all studies. One possible explanation is that bergamot preparation, extraction, and standardization varied in several studies.
• More recent studies suggest there is minimal to no significant evidence of statin-like activity for the whole extract in some analyses, highlighting the contested nature of the primary proposed mechanism.

References

• PubChem — Brutieridin (CID 45279710): Chemical structure, molecular formula, and properties
• Wikipedia — Brutieridin: Flavanone glycoside overview
• Di Donna et al. (2010), Journal of Agricultural and Food Chemistry — "On the Inhibitor Effects of Bergamot Juice Flavonoids Binding to the 3-Hydroxy-3-methylglutaryl-CoA Reductase (HMGR) Enzyme"
• Di Donna et al. (2010), Food Chemistry — "Recycling of industrial essential oil waste: Brutieridin and Melitidin, two anticholesterolaemic active principles from bergamot albedo"
• Di Donna et al. (2009) — "Statin-like Principles of Bergamot Fruit (Citrus bergamia): Isolation of 3-Hydroxymethylglutaryl Flavonoid Glycosides" (Academia.edu / ResearchGate)
• ResearchGate — Statin-like Principles of Bergamot Fruit: Isolation of 3-Hydroxymethylglutaryl Flavonoid Glycosides
• Leopoldini et al. (2021), Nutrients — "Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells"
• PMC — Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells (full text)
• PMC — "Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers" (2019 review)
• PMC — "The effect of bergamot polyphenolic fraction on lipid transfer protein system and vascular oxidative stress in a rat model of hyperlipemia"
• Impellizzeri et al. (2017), Nutrients — "Bioavailability of Bergamot (Citrus bergamia) Flavanones and Biological Activity of Their Circulating Metabolites in Human Pro-Angiogenic Cells"
• PMC — Bioavailability of Bergamot (Citrus bergamia) Flavanones and Biological Activity of Their Circulating Metabolites in Human Pro-Angiogenic Cells (full text)
• Gliozzi et al. (2013), International Journal of Cardiology — "Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia"
• Carresi et al. (2023), Journal of Functional Foods — "Bergamot (Citrus bergamia) peel extract as new hypocholesterolemic agent modulating PCSK9 expression"
• ResearchGate — "Hypocholesterolaemic activity of 3-hydroxy-3-methyl-glutaryl flavanones enriched fraction from bergamot fruit (Citrus bergamia): In vivo studies"
• Lamiquiz-Moneo et al. (2020), Critical Reviews in Food Science and Nutrition — Review of bergamot flavanones and lipid-lowering mechanisms
• PMC — "A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Effect of a Dietary Supplement Containing Dry Artichoke and Bergamot Extracts on Metabolic and Vascular Risk Factors in Individuals with Suboptimal Cholesterol Levels" (2024)
• PubMed — "Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study"
• PMC — "Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: Results from a 60-days Open-Label Study"
• Frontiers in Pharmacology — Low-Dose BPF in antipsychotic-treated patients: 60-day open-label study (full text)
• Nutrients (2025) — "Unveiling the Power of Bergamot: Beyond Lipid-Lowering Effects"
• The Skeptical Cardiologist — "Dietary Supplements for Lowering Cholesterol: Part 5, Bergamot" (critical evidence analysis)